News & Media

Maximizes Efficiency of Global Development and Commercialization Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, including $208 million or more in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties Total Committed Development Funding from all of Akebia’s Vadadustat Collaborations Plus Cash Exceeds $600 Million Akebia

PRINCETON, N.J., APRIL 19, 2017 - When a cowboy with a message of compassion and a desire to eliminate stigma connects with a company whose mission is creating products for better mental health worldwide, good things will happen. Jason DeShaw, a singer/songwriter and national award-winning mental health advocate from Montana, recently visited the Otsuka offices in Princeton, New Jersey to share

Acquisition of clinical-stage company in ADHD widens Otsuka’s presence in mental health Tokyo, Japan – March 3, 2017 – Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity

Funds Vadadustat Global Phase 3 PRO2TECT and INNO2VATE Studies Committed Capital and Milestone Payments Potentially Exceed $1 Billion Akebia and Otsuka Share Revenue and Commercialization Costs Equally Akebia to Host Conference Call at 8:30 a.m. Eastern Time Today  CAMBRIDGE,  MA  &  TOKYO,  JAPAN  --  December  20,  2016    Akebia  Therapeutics, Inc. (NASDAQ: AKBA) and